[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised

Roche's group sales increased by 7% at constant exchange rates in the first nine months of 2025, driven by strong demand for pharmaceuticals and diagnostics. The Pharmaceuticals Division saw a 9% increase, propelled by drugs like Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus. Diagnostics Division sales increased by 1%, with growth in pathology solutions and molecular diagnostics offsetting price impacts in China. Several key drugs received regulatory approvals in the US and EU, including Tecentriq, Gazyva/Gazyvaro, and Contivue. Phase III trials showed positive data for giredestrant in breast cancer and other studies advanced Alzheimer's and multiple sclerosis treatments. Roche announced an agreement to acquire 89bio for its MASH treatment. New diagnostic tools gained approval, including a blood test for Alzheimer's and an AI-based kidney function tool. The company is progressing ten potential new medicines into late-stage development and expects results for 19 new medicines by the end of the decade. Due to strong results, Roche raised its earnings outlook for 2025, expecting mid-single-digit sales growth and higher core earnings per share, while also anticipating an increase in its dividend.